A comprehensive view of OPKO Health Inc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Merck acquires Opko Health’s experimental MDX-2201 nanoparticle vaccine that targets Epstein-Barr virus for US$50.0M; the two companies to jointly develop the vaccine until FDA grants permission for clinical testing in deal worth up to nearly US$900.0M

Opko Health swings to Q1 net loss of US$55.4M from net income of US$31.1M a year ago, with consolidated revenue down at US$329.2M from US$545.2M a year ago; diagnostics revenue down at US$286.6M due to fewer COVID-19 tests, pharmaceuticals up at US$36.6M

Biopharmaceutical, diagnostics firm OPKO Health completes acquisition of ModeX Therapeutics for US$300M; ModeX Therapeutics develops multi-specific immune therapies for cancer and infectious diseases

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count